Literature DB >> 24188002

Development of DANDYs, new 3,5-diaryl-7-azaindoles demonstrating potent DYRK1A kinase inhibitory activity.

Stéphanie Gourdain1, Julien Dairou, Clément Denhez, Linh Chi Bui, Fernando Rodrigues-Lima, Nathalie Janel, Jean M Delabar, Kevin Cariou, Robert H Dodd.   

Abstract

A series of 3,5-diaryl-1H-pyrrolo[2,3-b]pyridines were synthesized and evaluated for inhibition of DYRKIA kinase in vitro. Derivatives having hydroxy groups on the aryl moieties (2c, 2j-l) demonstrated high inhibitory potencies with Kis in the low nanomolar range. Their methoxy analogues were up to 100 times less active. Docking studies at the ATP binding site suggested that these compounds bind tightly to this site via a network of multiple H-bonds with the peptide backbone. None of the active compounds were cytotoxic to KB cells at 10(-6) M. Kinase profiling revealed that compound 2j showed 2-fold selectivity for DYRK1A with respect to DYRK2 and DYRK3.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24188002     DOI: 10.1021/jm401049v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

1.  Synthesis and Structure-Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3- b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity.

Authors:  Sven Verdonck; Szu-Yuan Pu; Fiona J Sorrell; Jon M Elkins; Mathy Froeyen; Ling-Jie Gao; Laura I Prugar; Danielle E Dorosky; Jennifer M Brannan; Rina Barouch-Bentov; Stefan Knapp; John M Dye; Piet Herdewijn; Shirit Einav; Steven De Jonghe
Journal:  J Med Chem       Date:  2019-06-12       Impact factor: 7.446

2.  Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.

Authors:  Kunal Kumar; Peng Wang; Roberto Sanchez; Ethan A Swartz; Andrew F Stewart; Robert J DeVita
Journal:  J Med Chem       Date:  2018-08-21       Impact factor: 7.446

3.  Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.

Authors:  Kunal Kumar; Peter Man-Un Ung; Peng Wang; Hui Wang; Hailing Li; Mary K Andrews; Andrew F Stewart; Avner Schlessinger; Robert J DeVita
Journal:  Eur J Med Chem       Date:  2018-08-22       Impact factor: 6.514

Review 4.  DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.

Authors:  Amina Jamal Laham; Maha Saber-Ayad; Raafat El-Awady
Journal:  Cell Mol Life Sci       Date:  2020-09-01       Impact factor: 9.261

5.  10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.

Authors:  Hannes Falke; Apirat Chaikuad; Anja Becker; Nadège Loaëc; Olivier Lozach; Samira Abu Jhaisha; Walter Becker; Peter G Jones; Lutz Preu; Knut Baumann; Stefan Knapp; Laurent Meijer; Conrad Kunick
Journal:  J Med Chem       Date:  2015-03-23       Impact factor: 7.446

Review 6.  DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.

Authors:  Arnaud Duchon; Yann Herault
Journal:  Front Behav Neurosci       Date:  2016-06-03       Impact factor: 3.558

7.  DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives.

Authors:  Fernanda Neumann; Stéphanie Gourdain; Christelle Albac; Alain D Dekker; Linh Chi Bui; Julien Dairou; Isabelle Schmitz-Afonso; Nathalie Hue; Fernando Rodrigues-Lima; Jean M Delabar; Marie-Claude Potier; Jean-Pierre Le Caër; David Touboul; Benoît Delatour; Kevin Cariou; Robert H Dodd
Journal:  Sci Rep       Date:  2018-02-12       Impact factor: 4.379

Review 8.  The azaindole framework in the design of kinase inhibitors.

Authors:  Jean-Yves Mérour; Frédéric Buron; Karen Plé; Pascal Bonnet; Sylvain Routier
Journal:  Molecules       Date:  2014-11-28       Impact factor: 4.411

9.  Structure-Activity Relationships and Biological Evaluation of 7-Substituted Harmine Analogs for Human β-Cell Proliferation.

Authors:  Kunal Kumar; Peng Wang; Ethan A Swartz; Susmita Khamrui; Cody Secor; Michael B Lazarus; Roberto Sanchez; Andrew F Stewart; Robert J DeVita
Journal:  Molecules       Date:  2020-04-23       Impact factor: 4.411

10.  Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.

Authors:  Kunal Kumar; Peng Wang; Jessica Wilson; Viktor Zlatanic; Cecilia Berrouet; Susmita Khamrui; Cody Secor; Ethan A Swartz; Michael Lazarus; Roberto Sanchez; Andrew F Stewart; Adolfo Garcia-Ocana; Robert J DeVita
Journal:  J Med Chem       Date:  2020-02-19       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.